Core Insights - A research team from Liaoning He University and Shenyang He Eye Hospital published a study in the international journal "BMJ OPEN OPHTHALMOLOGY" comparing the vision-related quality of life and clinical efficacy of orthokeratology lenses (OK lenses), defocus glasses (DS glasses), and single vision glasses (SVS glasses) for myopic children and adolescents, providing important references for clinical choices in myopia optical interventions [1] Group 1 - The He Eye Hospital has actively responded to the national initiative "Light Project" by collaborating with Liaoning He University and He Eye Industry Group to establish a "365 Myopia Prevention and Control System" that utilizes big data, artificial intelligence, and genetic technologies [1] - This system emphasizes "precision" as a primary principle, customizing personalized plans based on genetic testing and vision examination data, addressing the shortcomings of traditional models [1] - The system covers the entire myopia development cycle, including prevention, early warning, control, and intervention, providing continuous management services [1] Group 2 - The integration of artificial intelligence and genetic diagnosis technologies allows for scientific risk prediction through myopia gene testing, enabling targeted measures to be taken [1] - The trend of early onset myopia is concerning, as high myopia, if not intervened in a timely manner, may lead to severe eye diseases such as retinal detachment [1] - Currently, SVS glasses are widely used due to their safety and affordability, while OK lenses and DS glasses are gradually gaining attention as new methods [1] Group 3 - The research team acknowledged limitations in their study and indicated the need for further research on the differences between various brands of lenses to provide more precise evidence for personalized correction plans [2]

Core Viewpoint - The research published in the international ophthalmology journal "BMJ OPEN OPHTHALMOLOGY" evaluates and compares the vision-related quality of life and clinical efficacy of different optical interventions for myopic children and adolescents in China, providing important references for clinical choices in myopia optical intervention [1] Group 1: Industry Context - The prevalence of myopia among children and adolescents in China is increasing, characterized by younger onset and more severe cases, which has raised significant social concerns [1] - The company actively responds to the national initiative "Light Project" by collaborating with various institutions to address myopia prevention and control [1] Group 2: Technological Integration - The establishment of the "365 Myopia Prevention and Control System" incorporates new technologies such as big data, artificial intelligence, and genetics to create personalized intervention plans based on genetic testing and vision examination data [1] - The system covers the entire myopia development cycle, including prevention, early warning, control, and intervention, providing continuous management services [1]

Group 1: Mergers and Acquisitions Strategy - The company adheres to a cautious and prudent investment principle when selecting merger targets, focusing on strategic alignment, compliance, value assessment, and acquisition methods [2][3][7] - The company aims to acquire medical targets in the ophthalmology consumer healthcare sector and upstream/downstream industry chain extensions [7][8] Group 2: Research and Development Investments - In 2024, the company increased R&D investments significantly, focusing on AI-assisted diagnosis and new intelligent devices, which are expected to enhance diagnostic efficiency and service capabilities [4][8][17] - The company achieved a post-operative satisfaction rate of over 98% through advanced equipment and innovative surgical techniques [3][4] Group 3: Financial Performance - The company reported a net profit of -27.4 million yuan in 2024, with a net profit margin of -3.22%, attributed to intensified industry competition and changes in medical insurance payment methods [8][9] - In Q1 2025, the company achieved a net profit of 32.5 million yuan, with a net profit margin of 11.16%, indicating a recovery compared to the previous year [8] Group 4: Internet Healthcare Development - The company's online healthcare platform has over 900,000 users and 120 online doctors, providing a range of services including consultations and health management [6][8] Group 5: Market Competition and Product Development - The company focuses on differentiated technology and customized products, such as the "Zhaoxing lens" and the "365 Myopia Prevention System," to strengthen its market position in vision care [9][10] - The company is actively monitoring advancements in gene therapy and AI-assisted surgical planning to maintain its competitive edge [8][9] Group 6: Social Responsibility and ESG Initiatives - The company has trained over 50,000 grassroots doctors and healthcare managers, contributing to public health and eye care accessibility [23][24] - The company integrates ESG principles into its operations, focusing on sustainable development and community health initiatives [25][26]